Leukotrienes and its antagonists in allergic disorders

Allergologia et Immunopathologia

Volumn 25, Issue 2, 1997, Pages 104-112

  Negro, J M ^a,d   Miralles, J C ^b   Ortiz, J L ^c   Funes, E ^a   Garcia A ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^b Allergology Section   (Spain)

^c Allergic Unit   (Spain)

^d NONE   (Spain)

Author keywords

Asthma drug therapy; FLP 55712; ICI 204219; Leukotriene antagonists; LY 171883; MK 0679; MK 751; NZ 107; ONO 1078; Rhinitis drug therapy; SK F 104353; U 75302

Indexed keywords

ANTIASTHMATIC AGENT; BRONCHODILATING AGENT; LEUKOTRIENE; LEUKOTRIENE RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT;

ANIMAL; CHEMICAL STRUCTURE; CLINICAL TRIAL; DRUG EFFECT; DRUG SCREENING; FORCED EXPIRATORY VOLUME; GUINEA PIG; HUMAN; HYPERSENSITIVITY; METABOLISM; NEUTROPHIL CHEMOTAXIS; PHYSIOLOGY; RESPIRATORY TRACT ALLERGY; REVIEW;

ANIMALS; ANTI-ASTHMATIC AGENTS; BRONCHODILATOR AGENTS; CHEMOTAXIS, LEUKOCYTE; CLINICAL TRIALS; DRUG EVALUATION, PRECLINICAL; FORCED EXPIRATORY VOLUME; GUINEA PIGS; HUMANS; HYPERSENSITIVITY; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENES; MOLECULAR STRUCTURE; RECEPTORS, LEUKOTRIENE; RESPIRATORY HYPERSENSITIVITY;

EID: 0031087446     PISSN: 03010546     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Feldberg W, Kellaway CH Liberation of histamine and formation of lysolethicin like substances by cobra venom. J Physiol 1938;94 187-226.
2. Kellaway CH, Threthewie RE The liberation of a slow reacting smooth muscle stimulating substance of anaphylaxis. J Exp Physiol 1940,30.121-45.
3. Samuelsson B Leukotrienes: mediators of immediate hypersensitivity reactions and imflammation Science 1983;220 (4597) 568-75
4. Borgeat P, Samuelson B. Transformation of arachidonic acid by rabbit polymorphonuclear leukocytes Formation of a novel dihydroxy eicosanoic acid. J Biol Chem 1979;254: 2643-6
5. Murphy RC, Hammarstrom S, Samuelsson B Leukotriene C: a slow reacting substance from murine mastocytoma cells. Proc Natl Acada Sci USA 1979,76:4275-9
6. Holtzman MJ. Arachidonic acid metabolism. Am Rev Respir Dis 1991;143(1):188-203
7. Crocker IC, Townley RG Leukotrienes. they receptors, antagonists and synthesis inhibitors. In. Townley RG, Agrawal DK, eds Immunopharmacology of allergic disease New York: Marcel Dekker, 1996:433-61.
8. Chung KF Leukotriene receptor antagonists and biosynthesis inhibitors. potential breakthrough in asthma therapy. Eur Respir J 1995;8(7):1203-13.
9. Naclerio RM, Baroody FM Observations on the response of the nasal mucosa to allergens. Otolaryngol Med Neck Surg 1994;111:3Pt 2 355-63
10. Snyder DW, Giles RE, Keith RA, Yee YK, Krell RD In vitro pharmacology if ICI-198,615. a novel, potent and selective peptide leukotriene antagonist. J Pharmacol Exp Ther 1987; 243(2):548-56
11. Adams GK, Lichtenstein LM. Antagonism of antigen induced contraction of guinea pig and human airways. Nature 1977; 270:255-7.
12. Lee TH, Walport MJ, Wilkinson AH, Tumer-Warwick M, Kay AB. Slow reacting substances of anaphylaxis antagonist FPL-55712 in chronic asthma. Lancet 1981,2.304-5
13. Austein T, Farmer JB, Lee TB, Sheard P, Tattersall ML Selective inhibitor of slow reacting substance of anaphylaxis Nat New Biol 1973;245:215-7.
14. Drazen JM. Leukotrienes in asthma and rhinitis. In Buse W, Holgate S, eds. Asthma and rhinitis Oxford: Blackwells, 1994.
15. 4 in atopic subjects. J Allergy Clin Immunol 1989;83(5):939-44
16. 4 receptor antagonist improves pulmonary function in patients with mild, chronic asthma. Am Rev Respir Dis 1989;140(5):1336-9
17. Israel E, Juniper EF, Callaghan JT, Mathur PN, Morris MM, Dowell AR et al. Effect of a leukotriene antagonist, LY-171883, on cold air-induced bronchoconstriction in asthmatics. Am Rev Respir Dis 1989;140(5).1458-3.
18. Ellis JL, Under BJ. Role of cysteinil-leukotrienes and histamine in mediating intrinsic tone in isolated human bronchi. Am J Respir Crit Care Med 1994;149(1):118-22
19. Christie PE, Smith CM, Lee TH. The potent and selective sulfidopeptide leukotriene antagonist, SK&F-104353, inhibits aspirin-induced asthma. Am Rev Respir Dis 1991,144(4) 957-8.
20. Robuschi M, Riva E, Fuccella LM, Vida E, Barnabe R, Rossi M et al Prevention of exercise-induced bronchoconstriction by a new leukotriene antagonist (SK&F-104353) A double-blind study versus disodium cromoglycate and placebo. Am Rev Respir Dis 1992;145(6).1285-8.
21. Bernstein PR. Accolate. Drugs Future 1994, 19: 217-20.
22. Krell RD The emergence of potent and selective peptide leukotriene receptor antagonists. Pulm Pharmacol 1989;2(1) 27-31.
23. 4-receptor antagonist, ICI-204219, relieves symptoms of acute seasonal allergic rhinitis Am J Respir Crit Care Med 1995,151(6).1734-9.
24. 4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialist Group. Am J Respir Crit Care Med 1994;150(3):618-23.
25. Nathan RA, Glass M, Minkwitz MC Inhaled ICI-204219 blocks antigen induced bronchoconstriction in subjects with asthma Chest 1994;105(2).483-8.
26. 4 receptor antagonist ICI-204219. Am Rev Respir Dis 1993;147(1):215-7.
27. 4 receptor antagonist ICI-204219. Am Rev Respir Dis 1990;141:Pt 1:988-92
28. Findlay SR, Barden JM, Easly CB, Glass M. Effect of the oral leukotriene antagonist, ICI-204219, on antigen-induced bronchoconstriction in subjects with asthma J Allergy Clin immunol 1992;89 (5):1040-5
29. Dahlen B, Zetterstrom O, Bjorck T, Dahlen SE. The leukotriene-antagonist ICI-204219 inhibits the early airway reaction to cumulative branchial challenge with allergen in atopic asthmatics. Eur Repir J 1994;7(2).324-31.
30. 4 receptor antagonist. Am Rev Respir Dis 1992;145.4 Pt 1 746-9.
31. 4 receptor antagonist ICI-204219 against exercise-induced asthma. Am Rev Respir Dis 1993;147:6 Pt 1:1413-8.
32. Hui KP, Barnes NC. Lung function improvement in asthma with a cysteinyl leukotriene receptor antagonist [See comments] Lancet 1991;337(8749):1062-3.
33. Spector SL, Smith LJ, Glass M The Accolate (ICI-204219) Clin Res 1993;41:199A
34. Townley RG, Glass M, Minkwitz MC Six-week, dose-escalation study with Accolate (zafirlukast) in patients with mild to moderate asthma. Am J Respir Crit Care Med 1995;151: A379
35. Taylor IK, O'Shaughnessy KM, Fuller RW, Dollery CT. Effect of cysteriyl-leukotriene receptor antagonist ICI-204219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects [See comments]. Lancet 1991,337 (8743):690-4.
36. 4 induced bronchoconstriction in subjects with asthma a concentration-effect study of ICI-204219. Clin Pharmacol Ther 1993,54(4):430-6
37. 4 receptor antagonist, ICI-204219, on antigen-induced bronchoconstriction in subjects with asthma. J Allergy Clin Immunol 1992;89(5).1040-5.
38. 2) induced bronchoconstriction in patients with mild to moderate asthma. Allergy 1995;50 Suppl.26:26.
39. Cohn J. Accolate™ (Zafirlukast) ACI International 1996;8(2): 69.
40. Howland W, Segal A, Glass M, Minkwitz MC. 6 week therapy with the oral leukotriene receptor antagonist, ICI-204219, in the treatment of asthma J Allergy Clin Immunol 1994,93 (1):A259.
41. Lockey RF, Lavins BJ, Sader L. Effects of 13 weeks of treatment with ICI-204219 (Accolate™) in patients with mild to moderate asthma J Allergy Clin Immunol 1995;95(1):A839.
42. Nathan RA, Glass M, Snader L. Effects of 13 weeks of treatment with ICI-204219 (Accolate™) or cromolin sodium (Intal®) in patients with mild to moderate asthma. J Allergy Clin Immunol 1995;95(1):A990
43. Spector S, Miller CJ, Glass M. 13-week dose-response study with Accolate™ (Zafirlukast) in patients with mild to moderate asthma. Allergy 1995;Suppl 26:117.
44. Kemp JP, Glass M, Minkwitz MC Onset of action of the leukotriene receptor antagonist, zafirlukast (Accolate™), in patients with asthma. J Allergy Clin Immunol 1995,95(1): A844.
45. Suissa S, Dennis R, Ernst P, Sheehy O, Wood-Dauphine S. Cost-effectiveness of Zafirlukast (Accolate™) in mild-to-moderate asthma Allergy 1996;51 Suppl. 30.84.
46. 4) antagonist ICI-204219 relieves ragweed allergic rhinitis symptoms. J Allergy Clin Immunol 1993,91:997-104.
47. Nabe T, Kohno S, Tanpo T, Saeki Y, Yamamura H, Horiba M et al. Inhibitory effect of ONO-1078 on specific binding of peptide lekotrienes to human lung crude membrane. Prostaglandins Leukot Essent Fatty Acids 1994,51(3) 163-71
48. Taki F, Suzuki R, Torii K, Matsumoto S, Taniguchi H, Takagi K. Reduction of the seventy of bronchial hyperresponsiveness by the novel leukotriene antagonist 4-oxo-8-(4-phenyl-butoxy) benzoylamino]-2-(tetrazol-5-yl)-4H-1-benzopyran hemihydrate Arzneimittelforschung 1994,44(3).330-3.
49. Yamai T, Watanabe S, Motojima S, Fukada T, Makino S The significance of leukotriene in antigen-induced late asthmatic response. Am Rev Respir Dis 1989,139:A462.
50. Yamamoto H, Nagata M, Kuramitsu K, Kiuchi H, Sakamoto Y, Yamamoto K et al Inhibition of analgesic induced asthma by leukotriene receptor antagonist ONO-1078. Am J Respir Crit Care Med 1994;150(1):254-7.
51. Nakagawa T, Mizushima Y, Ishii A, Nambu F, Motoishi M, Yui Y et al. Effect of leukotriene antagonist on experimental and clinical bronchial asthma. Adv Prostaglandin Thromboxane Leukotriene Res 1990;21:465-8
52. Obata T, Okada Y, Motoishi M, Nakagawa N, Terawaki T, Aishita H In vitro antagonism of ONO-1078, a newly developed anti-asthma agent, against peptide leukotrienes in isolated guinea pig tissues. Jpn J Pharmacol 1992,60(3):227-37.
53. Fujimura M, Sakamoto S, Kamio Y, Matsuda T Effect of a leukotriene antagonist, ONO-1078, on bronchial hyperresponsiveness in patients with asthma. Respir Med 1993, 87(2):133-8.
54. Foster A, Chan CC. Peptide leukotriene involvement in pulmonary eosinophil migration upon antigen challenge in the actively sensitized guinea pig Int Arch Allergy Appl Immunol 1991;96(3) 279-84.
55. 4 receptor antagonist. Can J Physiol Pharmacol 1989;67(1).17-28.
56. 4 receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma. J Allergy Clin Immunol 1993,90(2):193-201.
57. 4 receptor antagonist, in patients with chronic asthma. I Allergy Clin Immunol 1991,87 309.
58. 4 induced bronchoconstriction in the human Am Rev Respir Dis 1991,144.3 Pt 1 617-21.
59. 4 receptor antagonist [See comments]. N Engl J Med 1990;323(25): 1736-9.
60. 4 antagonist, MK-679 Am Rev Respir Dis 1993;147:6 Pt 1:1442-6.
61. 43 receptor antagonist, in patients with chronic asthma. Eighth International Conference on Prostaglandins and Related Compounds, July 1992, 163
62. Dahlen B, Kumlin M, Margolskee DJ, Larsson C, Blomqvist H, Williams VC et al. The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysineaspirin in aspirin-sensitive asthmatics. Eur Respir J 1993,6 (7):1018-26.
63. Henderson WR The role of leukotrienes in imflammation Ann Intern Med 1994;121(9):684-97
64. Bando T, Fujimura M, Shintani H, Saito M, Kurashima K, Nishi K et al. Inhibitory effect of aerosol administration of a sulfidopeptide leukotriene antagonist on bronchoconstriction induced by antigen inhalation in guinea pigs. Arzneimittelforschung 1994,44(6):754-7
65. Saito M, Fujimura M, Ogawa H, Matsuda T. Role of leukotrienes and platelet activating factor in allergic broncho-constriction and their interactions in guinea pig airway in vivo. Prostaglandins Leukot Essent Fatty Acids 1993,49(2): 579-85.
66. Aibara S, Mori M, Tsukada W. Inhibitory effect of DS-4574 on leukotriene or antigen-induced bronchoconstriction in guinea pigs Int Arch Allergy Immunol 1993,100(3):268-73.
67. Tabuchi Y, Kurebayashi Y. Effect of DS-4574, a novel peptidoleukotriene antagonist with mast cell stabilizing action, on acute gastric lesions and gastric secretion in rats Jpn J Pharmacol 1992;60(4):335-40
68. Iwama T, Nagai H, Koda A. Effects of NZ-107 on airway inflammation and cell activation in guinea-pigs. J Pharm Pharmacol 1993;45(4):286-91.
69. 4 antagonist U-75302 on antigen-induced bronchopulmonary eosinophiliia in sensitized guinea pigs. Am Rev Respir Dis 1989,140(6). 1712-6.